Safety concerns dominate early trial of experimental lupus therapy
Those receiving iberdomide were more prone to discontinuation, infections and neutropenia
The experimental drug iberdomide may provide clinically significant symptom relief in patients with SLE, but only at high doses, new research shows.
Results from the Bristol Myers Squibb-funded phase II trial have shown that those prescribed the immunomodulator are more likely to experience a reduction in disease activity versus placebo.
The US researchers concede, however, that the high rate of adverse events and treatment discontinuation suggest a need for longer trials to better gauge the drug’s efficacy and safety.
Iberdomide is a high-affinity cereblon modulator that promotes the degradation of the transcription factors Ikaros and Aiolos.
